USPs that matters:

New: Rare Earth-Themefolio

Advanced IPO-Section: Equities & ETF (link)

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

Short Selling Radar

IPO InfoDataHub

Powerful & free of charge: Tools 4 WebMaster ...

Tipp: Exclusive Newswire Digest

Info-Hub

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Campus

KnowHow & Education
Advanced Event Calendar Feed
Mentoring & Coaches

Press

FAQ

What's New

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Home
Terminal
M1 Kliniken AG

M1 Kliniken AG

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

D54872110

SEDOL

BYQC665

CIK

N/A

m1-kliniken.de

LEI: 529900W697S31A26WT02

New: Infographics X-Lab

FIGI: BBG00B02V2J1

M12

M1 Kliniken AG

GICS: - · Sector: EQTY · Sub-Sector: -

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

M1 Kliniken

Click to initiate

ENTERPRISE

You are not logged in. Don't worry! Click here and see what Perplexity AI knows about $M12.

NAME

M1 Kliniken AG

ISIN

DE000A0STSQ8

TICKER

M12

MIC

XETR

REUTERS

M12.DE

BLOOMBERG

M12 GR

F&G: 63

24.466,83 DAX · 15,60 Vola-Index · 118.956,51 BTC · 1,16626 EURUSD

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading

Knock out & Barriers (IG)

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Thu, 19.06.2025

Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH 19.06.2025 / 12:46 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer...

Research & Analysis

Thu, 05.06.2025

M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31 Berlin, 5 June 2025 – M1 Kliniken AG (ISIN: DE000A0STSQ8) has made a strong start to the 2025 financial year and continues its profitable growth trajectory. The significant improvement in earnings results from the consistent implementation of efficiency measures...

Research & Analysis

Wed, 21.05.2025

M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership Berlin, 21/05/2025 - M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its annual report for the 2024 financial year. The M1 Group continued on its growth trajectory, driven in particular by the high-margin Beauty segment. Looking ahead, the company sees...

Research & Analysis

Tue, 29.04.2025

M1 Kliniken AG publishes preliminary figures for the 2024 financial year: Strong EBIT growth (+70%) and significant increase in earnings per share (+57%) Berlin, April 29, 2025 - M1 Kliniken AG (ISIN: DE000A0STSQ8) has published its preliminary IFRS consolidated figures for the 2024 financial year. The Group once again recorded strong growth in i...

Research & Analysis

Tue, 01.04.2025

M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are c...

Research & Analysis

Tue, 17.12.2024

Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH 17.12.2024 / 12:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude ...

Research & Analysis

Tue, 19.11.2024

M1 Kliniken AG increases operating profit (EBIT) by 71% in the first nine months of 2024 and confirms medium-term targets Group: sales +8.7% to EUR 257.22 million and EBIT +70.7% to EUR 22.09 million Beauty segment growth driver with sales +33.5% to EUR 71.02 million EBIT in the Beauty segment +30.4% to EUR 16.26 million Medium-term target c...

Research & Analysis

Fri, 06.09.2024

Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH 06.09.2024 / 14:30 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude ...

Research & Analysis

Tue, 03.09.2024

Operating Profit (EBIT) almost doubled: M1 Kliniken AG also grows significantly in the first half of 2024 Group: sales +11.2% to EUR 167.7 million and EBIT +98.8% to EUR 14.5 million Earnings per share increased from EUR 0.17 to EUR 0.53 Beauty segment: sales +30.6% and EBIT +24.3% Profitable growth to be continued Berlin, 03.09.2024 –...

Research & Analysis

Fri, 21.06.2024

M1 Kliniken AG: Management Board confirms growth targets Berlin, 21 June 2024 - As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG (ISIN: DE000A0STSQ8) for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG. Attila Strauss emphasis...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

BARRISTA SMART * AD

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 25.314 Visitors - 22.726 Registered members - 10 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Congratulation India

celebrating National Holiday

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Visual Sitemap

Helpdesk

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Consumer information

Imprint

smart.AD